CN114246905A - Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating coronary heart disease and restenosis after PCI (percutaneous coronary intervention) operation - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating coronary heart disease and restenosis after PCI (percutaneous coronary intervention) operation Download PDFInfo
- Publication number
- CN114246905A CN114246905A CN202111049234.1A CN202111049234A CN114246905A CN 114246905 A CN114246905 A CN 114246905A CN 202111049234 A CN202111049234 A CN 202111049234A CN 114246905 A CN114246905 A CN 114246905A
- Authority
- CN
- China
- Prior art keywords
- restenosis
- traditional chinese
- chinese medicine
- pci
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 23
- 201000000054 Coronary Restenosis Diseases 0.000 title claims description 4
- 206010056489 Coronary artery restenosis Diseases 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 238000013146 percutaneous coronary intervention Methods 0.000 title description 32
- 241000208340 Araliaceae Species 0.000 claims abstract description 40
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 40
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 40
- 235000008434 ginseng Nutrition 0.000 claims abstract description 40
- 208000037803 restenosis Diseases 0.000 claims abstract description 40
- 238000005728 strengthening Methods 0.000 claims abstract description 27
- 241000405414 Rehmannia Species 0.000 claims abstract description 9
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 4
- 244000197580 Poria cocos Species 0.000 claims abstract description 4
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 206010020718 hyperplasia Diseases 0.000 claims description 8
- 230000002980 postoperative effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 4
- 230000012292 cell migration Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 238000007887 coronary angioplasty Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 claims description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 2
- 238000002679 ablation Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000003416 Asparagus officinalis Species 0.000 claims 1
- 235000005340 Asparagus officinalis Nutrition 0.000 claims 1
- 241000759833 Cornus officinalis Species 0.000 claims 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 claims 1
- 229930195210 Ophiopogon Natural products 0.000 claims 1
- 244000248557 Ophiopogon japonicus Species 0.000 claims 1
- 208000002528 coronary thrombosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 240000006766 Cornus mas Species 0.000 abstract description 3
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000000702 aorta abdominal Anatomy 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 229940107131 ginseng root Drugs 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 229960004796 rosuvastatin calcium Drugs 0.000 description 4
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 244000248539 Asparagus cochinchinensis Species 0.000 description 1
- 235000009292 Asparagus cochinchinensis Nutrition 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000006117 ST-elevation myocardial infarction Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000005077 saccule Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a ginseng root-strengthening traditional Chinese medicine composition prepared from ginseng, rehmannia glutinosa, poria cocos, moutan bark, prepared rehmannia root, dogwood, Chinese yam, rhizoma alismatis, radix asparagi and radix ophiopogonis in preparation of a medicine for preventing and/or treating restenosis after PCI (coronary heart disease) operation.
Description
Technical Field
The invention relates to a new application of a traditional Chinese medicine composition, in particular to an application of the traditional Chinese medicine composition in preparing a medicine for treating restenosis after PCI operation, and belongs to the technical field of medicines.
Background
Coronary Heart Disease (CHD) is one of the diseases seriously harming human health at present, and statistics show that the morbidity and mortality of coronary heart disease in China are in an increasing trend. Percutaneous Coronary Intervention (PCI) has become an important means for treating coronary heart disease, but Restenosis (RS) rate in stent is as high as 30-50% after 6 months of operation, which seriously affects its long-range curative effect. The application of various stents greatly reduces the restenosis rate after PCI operation, but still can not radically cure the restenosis, so that the clinical application and development of the PCI operation are limited. Therefore, prevention and treatment of restenosis after PCI surgery becomes a significant challenge facing cardiovascular diseases in China at present.
The occurrence mechanism of restenosis after PCI operation is mainly considered by Western medicine to be local inflammatory infiltration, platelet adhesion, thrombosis, vascular smooth muscle cell proliferation and migration, intimal hyperplasia, elastic recoil, vascular remodeling and the like, and is generally considered to be hyperproliferation of vascular smooth muscle cells. Western medicine for preventing and treating coronary heart disease and restenosis after PCI operation is used in preparing medicine for resisting blood platelet, anticoagulant, statin, etc. Evidence shows that the patients undergoing PCI operation, especially ST-elevation myocardial infarction patients, insisting on taking clopidogrel is important for preventing and treating postoperative restenosis. However, the risk of bleeding is increased by taking anti-platelet drugs such as clopidogrel and aspirin for a long time, and other diseases can be induced.
The restenosis after PCI still belongs to the category of the chest stuffiness in traditional Chinese medicine, and various doctors have different insights about the pathogenesis of RS. Generally, the mechanism of restenosis after PCI operation, which is considered by traditional Chinese medicine, has the following four aspects: (1) the secondary excess is mainly marked by blood stasis, phlegm turbidity and heat-toxicity. (2) The principal deficiency with secondary excess is qi deficiency with blood stasis, deficiency of both qi and yin, blood stasis with turbid phlegm. (3) Theory of collateral diseases. (4) Theory of repair of injury. At present, medicines for tonifying qi and activating blood circulation, eliminating phlegm and removing blood stasis are mostly adopted for traditional Chinese medicine prevention and treatment of PCI postoperative restenosis, and patent 201410530321.2 discloses a traditional Chinese medicine composition which mainly utilizes traditional Chinese medicine effects of promoting blood circulation and removing blood stasis, dredging collaterals, tonifying qi and warming yang, and is assisted by the theory of relieving chest stuffiness and benefiting diaphragm, relieving restlessness and resolving depression to treat restenosis after myocardial infarction, so that a certain effect is achieved.
Disclosure of Invention
The invention is a new application of the ginseng root-securing oral liquid on the basis of the clinical feedback of the existing Chinese patent medicine product 'ginseng root-securing oral liquid', namely a new application of the ginseng root-securing oral liquid in treating restenosis diseases after PCI (coronary heart disease) operation. The invention aims to provide a new Chinese patent medicine product for treating restenosis after PCI (coronary heart disease) operation, and the medicine selectivity of a patient is increased.
The invention aims to provide application of a traditional Chinese medicine composition mainly prepared from ginseng, rehmannia root, prepared rehmannia root, dogwood fruit, Chinese yam, tree peony bark, oriental waterplantain rhizome, poria cocos, asparagus fern and dwarf lilyturf tuber in preparing medicines for treating coronary heart disease PCI postoperative restenosis.
The restenosis after the PCI operation of the coronary heart disease comprises, but is not limited to, restenosis after percutaneous balloon coronary angioplasty, restenosis after coronary stent implantation and restenosis after ablation technology of atheromatous plaque.
The restenosis disease after percutaneous saccule coronary angioplasty comprises but is not limited to postoperative coronary local inflammatory reaction, thrombosis formation, platelet adhesion, vascular smooth muscle cell proliferation and migration, intimal hyperplasia, elastic retraction and vascular reconstruction.
The intimal hyperplasia includes an increase in intimal thickness and intimal area.
The second purpose of the invention is to provide a traditional Chinese medicine preparation containing the traditional Chinese medicine composition, namely the traditional Chinese medicine composition can be prepared into clinically acceptable dosage forms directly by a conventional process or after pharmaceutically acceptable auxiliary materials are added.
The clinically acceptable dosage form is one or more of capsules, tablets, granules, pills and oral liquid;
the traditional Chinese medicine composition is a ginseng root-strengthening traditional Chinese medicine composition;
the ginseng root-strengthening traditional Chinese medicine composition is a ginseng root-strengthening oral liquid.
The ginseng root-strengthening traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 60-90 parts of ginseng, 170 parts of rehmannia root 130-.
Animal experiments show that the ginseng root-strengthening oral liquid prepared from the traditional Chinese medicine composition can relieve the thickening of the inner membrane of the abdominal aorta of a restenosis model rabbit after a PCI (percutaneous coronary intervention) operation, reduce the area increase of the inner membrane and the area ratio of the middle membrane, and has the effects of relieving intimal hyperplasia and improving the restenosis after the PCI operation.
The invention has the following advantages:
the ginseng root-strengthening oral liquid provided by the invention is prepared from ginseng, rehmannia root, poria cocos, moutan bark, prepared rehmannia root, dogwood fruit, Chinese yam, rhizoma alismatis, asparagus cochinchinensis and radix ophiopogonis, has definite medicinal components, reasonable compatibility and good clinical use safety, and solves the problem that postoperative restenosis in the prior coronary heart disease intervention technology influences the curative effect.
The basic pathogenesis of restenosis after PCI (coronary heart disease) operation is' essential deficiency and excess, which is considered by traditional Chinese medicine and comprises qi deficiency and blood stasis, deficiency of both qi and yin, blood stasis and phlegm turbidity, early heart qi deficiency, excessive yin and blood damage in the middle period and yin and yang and qi and blood damage in the later period. The traditional Chinese medicine treatment should adopt the functions of invigorating qi and activating blood circulation, nourishing yin and kidney, promoting qi circulation and relieving depression, expelling phlegm and removing dampness and resolving turbidity. The ginseng root-strengthening oral liquid has the effects of tonifying qi and yin and strengthening the foundation and can be used for treating deficiency of yin and weak qi, consumptive disease cough, palpitation and shortness of breath, bone-steaming tidal fever, waist soreness and tinnitus, spermatorrhea and night sweat, and dry stool, and plays the advantages of integral treatment and disease-seeking basis in symptomatic treatment corresponding to the pathogenesis of traditional Chinese medicine, so that the oral liquid is used for preventing and treating restenosis after PCI (coronary heart disease) operation, effectively relieves hyperplasia of intimal cells after PCI operation, and achieves the effect of preventing and treating restenosis after PCI operation of coronary heart disease.
Detailed Description
The application of the invention is derived from clinical use feedback of the ginseng root-strengthening oral liquid. In the clinical use process of the ginseng root-securing oral liquid, the ginseng root-securing oral liquid is unexpectedly found to improve clinical symptoms of angina, coronary artery angiography stenosis and the like of a patient to a certain extent for the individual patient with the coronary heart disease PCI postoperative restenosis disease.
Based on the clinical use feedback of the ginseng root-securing oral liquid, the inventor develops a series of developments aiming at the application of the ginseng root-securing oral liquid in the treatment of coronary heart disease, and in order to verify the efficacy of the ginseng root-securing oral liquid in the treatment of restenosis after PCI (coronary heart disease) operation, the inventor carries out animal experimental research, and only a part of experimental models are taken as examples to explain the restenosis after PCI operation or restenosis after other angioplasty recorded in the specification, and the inventor also carries out pharmacological experimental research, so that the composition can achieve the same or similar effect, and the effects are not described one by one.
Example 1 Effect of Ginseng radix oral liquid for consolidating constitution on the proliferation of intima hyperplasia of abdominal aorta of rabbit model of restenosis after PCI operation
Test drugs:
the ginseng root-strengthening oral liquid sold in the market is 10ml per bottle, Lunan Thick pharmaceutical Co.
Commercially available aspirin, 100 mg/tablet, Bayer pharmaceutical group, Inc.
Commercially available rosuvastatin calcium tablet, 5mg, lucinanfibrate pharmaceutical ltd.
Mixed liquid of rosuvastatin calcium and aspirin: each ml of the mixed solution contains 0.27mg of aspirin and 0.32mg of rosuvastatin calcium.
Experimental animals and feed:
the weight of a healthy New Zealand big ear white rabbit is 2-2.5kg, 60 rabbits are suitable for feeding for one week before the experiment, and the number of the rabbits is not limited by the number of the females.
Rabbit high fat feed composition: 79% of common rabbit feed, 15% of egg yolk powder, 5% of lard and 1% of cholesterol.
Grouping: the experimental animals are randomly divided into a blank group, a model group, a positive control group, a ginseng root-strengthening oral liquid low-dose group, a ginseng root-strengthening oral liquid medium-dose group and a ginseng root-strengthening oral liquid high-dose group according to the weight, and each group contains 10 animals.
Molding: except for the blank group of animals normally fed, 5 groups were given high fat diet for 4 weeks to create an atherosclerosis model, followed by abdominal aortic intimal stripping surgery modeling: taking 1.5ml/kg of sodium pentobarbital with the concentration of 2.5 percent for intravenous anesthesia, fixing an animal, depilating and disinfecting the right inguinal part, then carrying out small amount of local anesthesia on lidocaine, slicing, fleshing and separating femoral artery, respectively clamping the proximal and distal end of the femoral artery to expose about 2cm, cutting off one third of the circumference of the artery, introducing a balloon catheter (which is determined according to the diameter of a blood vessel) with the diameter of 1.5-2.0mm into the lower part of the renal artery, filling the balloon with saline water with the pressure of 4-6Kpa, slowly pulling the catheter back to the incision to evacuate the liquid in the balloon, reducing the pressure to zero, repeating the process for 3 times, and achieving the purpose of peeling off the abdominal aorta endothelium. The catheter was withdrawn, the femoral artery was ligated, the skin was sutured, and penicillin was continuously administered to the affected area for 3 days, 80 uU/day, to prevent infection.
Administration: feeding the animals in each group with normal feed after operation, starting administration on the next day, and performing intragastric administration on each group according to the following scheme, wherein the administration is performed for 1 time per day and is continuously performed for 4 weeks, and the administration dose is converted according to a conversion table of equivalent doses of human and animals:
blank group: normal saline was administered at a dose of 10ml/kg
Model group: normal saline was administered at a dose of 10ml/kg
Positive control group: administering a mixture of aspirin and rosuvastatin calcium at a dose of 10ml/kg
The ginseng root strengthening oral liquid low dose group comprises: the ginseng root strengthening oral liquid is given, and the dosage is 0.94ml/kg
The ginseng root-strengthening oral liquid comprises the following dosage groups: the ginseng root strengthening oral liquid is given, and the dosage is 1.88ml/kg
The ginseng root strengthening oral liquid high-dose group comprises: the ginseng root strengthening oral liquid is given, and the dosage is 3.76ml/kg
After 4 weeks, the white rabbits with big ears in New Zealand are killed, the abdominal cavity is exposed by cutting the abdominal wall, the intestinal canal is turned to one side, the abdominal aorta and the inferior vena cava are seen to be parallel to the side of the spinal column, the abdominal aorta is separated, 2cm long abdominal aorta is cut out, washed by physiological saline and then fixed in 10 percent formaldehyde solution, then dehydrated by alcohol, transparent by xylene, embedded by conventional paraffin, and stained by section, the intimal thickness, the intimal area and the media area of the section are measured by Imaging-Pro Plus6.0 image processing software, and the intimal-media area ratio is calculated, and the result is shown in Table 1.
Data mining
Represents the t-test and one-way analysis of variance, P, using a sps 10.0<0.01 indicates that the difference is very significant, P<0.05 means that the difference is significant and statistically significantAnd (5) defining.
Results of the experiment
Table 1 effect of ginseng root-securing oral liquid on intimal thickness and area in rabbit left iliac artery at 4 weeks after surgery (n-10,
)
p < 0.05, P < 0.01 compared to blank; comparison with model group#P＜0.05
As shown in Table 1, compared with the blank group, the thickness of the intima, the area of the intima and the area ratio of the intima to the media of the intima of the model group are increased, the difference is very obvious (P is less than 0.01), and the statistical significance is achieved; the difference of the mesomembrane area is not obvious and has no statistical significance (P is more than 0.05). Compared with the model group, the ginseng root-strengthening oral liquid has the advantages that the intima thickness, the intima area and the intima-media area ratio of the low, medium and high dose groups are all reduced, the difference is obvious (P is less than 0.05), and the statistical significance is achieved. Therefore, the ginseng root-strengthening oral liquid can relieve the thickening of the blood vessel intima, reduce the area increase of the intima and the area ratio of the intima to the intima-media, and has the effects of resisting intimal hyperplasia and improving the restenosis of the artery after PCI.
Claims (9)
1. Application of ginseng root-strengthening traditional Chinese medicine composition in preparing medicine for preventing and/or treating coronary heart disease and restenosis after PCI operation.
2. The use of claim 1, wherein the post-PCI restenosis of coronary heart disease is selected from the group consisting of post-percutaneous balloon coronary angioplasty restenosis, post-coronary stent restenosis, post-ablation restenosis of atheromatous plaque.
3. The use according to claim 1, wherein the restenosis disease after PCI surgery in coronary heart disease is post-operative coronary thrombosis, platelet adhesion, vascular smooth muscle cell proliferation and migration, intimal hyperplasia, recoil or vascular remodeling.
4. The use of claim 1, wherein the ginseng root-strengthening Chinese medicinal composition is prepared from ginseng, rehmannia root, poria cocos, moutan bark, prepared rehmannia root, cornus officinalis, Chinese yam, alisma orientale, asparagus and ophiopogon root.
5. The use of claim 4, wherein the ginseng root-strengthening traditional Chinese medicine composition is prepared from the following medicinal materials in parts by weight: 60-90 parts of ginseng, 170 parts of rehmannia root 130-.
6. The use as claimed in any one of claims 1 to 5, wherein the ginseng root-strengthening traditional Chinese medicine composition further comprises one or more pharmaceutically acceptable pharmaceutical excipients.
7. The use as claimed in any one of claims 1 to 5, wherein the ginseng root-strengthening traditional Chinese medicine composition is processed into capsules, tablets, granules, powder, pills or oral liquid by the prior art.
8. The use of claim 7, wherein the ginseng root-securing traditional Chinese medicine composition is a ginseng root-securing oral liquid.
9. The use of any one of claims 1-5, wherein the ginseng root-securing traditional Chinese medicine composition can be used in combination with other conventional medicines for improving the symptoms of restenosis after PCI surgery in coronary heart disease.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020109965763 | 2020-09-21 | ||
| CN202010996576 | 2020-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114246905A true CN114246905A (en) | 2022-03-29 |
Family
ID=80791459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111049234.1A Pending CN114246905A (en) | 2020-09-21 | 2021-09-08 | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating coronary heart disease and restenosis after PCI (percutaneous coronary intervention) operation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114246905A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1958039A (en) * | 2006-11-24 | 2007-05-09 | 王建兴 | Preparation of Chinese traditional medicine for treating cardiovascular disease, and cerebrovascular disease |
| US20070254938A1 (en) * | 2004-07-01 | 2007-11-01 | Kiyoshi Ichikawa | Preventive or Therapeutic Agent for Vascular Intimal Proliferative Disease |
| CN103816368A (en) * | 2014-03-12 | 2014-05-28 | 李正梅 | Extraction method and application of ginseng-containing plant composition |
| CN106039204A (en) * | 2016-06-06 | 2016-10-26 | 王嘉兴 | Traditional Chinese medicine composition for treating restenosis after coronary intervention and preparation method of traditional Chinese medicine composition |
| CN106370749A (en) * | 2016-08-29 | 2017-02-01 | 鲁南厚普制药有限公司 | Quality detection method of ginseng basis-consolidating oral solution |
-
2021
- 2021-09-08 CN CN202111049234.1A patent/CN114246905A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070254938A1 (en) * | 2004-07-01 | 2007-11-01 | Kiyoshi Ichikawa | Preventive or Therapeutic Agent for Vascular Intimal Proliferative Disease |
| CN1958039A (en) * | 2006-11-24 | 2007-05-09 | 王建兴 | Preparation of Chinese traditional medicine for treating cardiovascular disease, and cerebrovascular disease |
| CN103816368A (en) * | 2014-03-12 | 2014-05-28 | 李正梅 | Extraction method and application of ginseng-containing plant composition |
| CN106039204A (en) * | 2016-06-06 | 2016-10-26 | 王嘉兴 | Traditional Chinese medicine composition for treating restenosis after coronary intervention and preparation method of traditional Chinese medicine composition |
| CN106370749A (en) * | 2016-08-29 | 2017-02-01 | 鲁南厚普制药有限公司 | Quality detection method of ginseng basis-consolidating oral solution |
Non-Patent Citations (3)
| Title |
|---|
| 刘薇;: "PCI术后再狭窄的中医辨证论治探析", 河南中医, vol. 31, no. 11, pages 1220 - 1221 * |
| 方显明;: "冠心病介入术后的中医药康复治疗述评", 广西中医学院学报, vol. 12, no. 03, pages 58 - 60 * |
| 杨志华;刘琰;闫海峰;姬艳苏;王淑萍;: "基于网络药理学的六味地黄丸治疗冠心病的分子机制研究", 云南中医学院学报, vol. 42, no. 03, pages 74 - 82 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111888396B (en) | Pharmaceutical composition for treating cervical spondylosis and preparation method and application thereof | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN105833229A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating myocardial infarction | |
| CN114246905A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating coronary heart disease and restenosis after PCI (percutaneous coronary intervention) operation | |
| CN101757443A (en) | Traditional Chinese medicine preparation for treating hemophilia | |
| CN115518085A (en) | Pharmaceutical composition containing Pleurotus tuber-regium extract as effective component for preventing or treating gynecological diseases | |
| CN100425252C (en) | Medicine for treating leukopenia | |
| KR101911877B1 (en) | Functional food composition comprising herbal medicinal extracts | |
| CN101439088B (en) | Medicament for promoting leucocyte hyperplasia | |
| CN101732413B (en) | Chinese medicinal composition for treating arthromyodynia and preparation method thereof | |
| CN110420320A (en) | A kind of Chinese medicine composition for removing gout pathogenesis basis | |
| CN107875200A (en) | A kind of Chinese medicine composition of effectively treatment tinea pedis | |
| CN117414398B (en) | Traditional Chinese medicine composition and application thereof in treating vasculitis | |
| CN100384442C (en) | Chinese herbal medicine preparation and its preparing process and application | |
| JP2941160B2 (en) | Relief agent for shingles pain | |
| CN1092519C (en) | Chinese medicine for argiitis | |
| CN103768454A (en) | Composition for preventing and treating HIV/AIDS (Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome) and preparation method thereof | |
| CN111643557B (en) | Pharmaceutical composition for preventing and treating sequela of deep venous thrombosis of lower limbs and preparation method and application thereof | |
| CN101721471B (en) | Leucocyte-raising medicine containing leucogen | |
| CN106620070A (en) | Medicinal composition for treating osteoarthropathy and preparation method and application thereof | |
| CN109419844B (en) | Tibetan medicine composition for treating osteoarthritis pain | |
| CN105521335A (en) | Traditional Chinese medicine for treating paroxysmal supraventricular tachycardia and preparation method of traditional Chinese medicine | |
| CN113171462A (en) | Pharmaceutical composition and preparation method and application thereof | |
| KR20040030376A (en) | Pharmaceutical composition for treatment of thrombosis | |
| KR20190042147A (en) | Composition for treating edema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |